P3 Health Partners Earnings Call Highlights Growth, Profitability
P3 Health Partners (PIII) reported Q3 earnings with 15% revenue growth, $21M Adjusted EBITDA, and raised 2026 guidance to $90M-$110M. Challenges include higher outpatient costs and lower at-risk membership. Management highlighted medical-cost control, quality gains, and expansion plans.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise are likely to drive short‑term price appreciation, though cost pressures remain a risk.
Market read
Earnings beat and guidance raise make the stock a near‑term candidate for buying on momentum.
What to watch
Rising Nevada costs and at‑risk membership decline could offset upside.
Background
P3 Health Partners reported Q3 results with revenue up 15% YoY and lifted its 2026 EBITDA guidance.
Ticker impact
Q3 earnings call disclosed 15% revenue growth, $21M Adjusted EBITDA and raised full-year guidance to $90M-$110M.
likely upward pressure as market prices in higher earnings outlook
Management highlighted three consecutive profitable quarters and lifted the EBITDA midpoint, which typically supports a price rally.
Market effects
Positive earnings may boost sentiment in the Medicare Advantage and health services sector.
U.S. healthcare stocks could see modest gains.
Limited to U.S. health‑care investors.
Counterpoint
Guidance raise may already be priced in; watch for higher outpatient cost pressure.
Key entities
- companyP3 Health Partners Inc.
Provider of Medicare Advantage services.

